Effect of chloroquine on the apoptosis of tongue squamous cell carcinoma SCC25 cells induced by bleomycin and nedaplatin
Abstract
Objective: To study the effect and mechanism of chloroquine-induced chemotherapy drugs bleomycin and nedaplatin on apoptosis of tongue squamous cell carcinoma SCC25 cells. Methods: The inhibitory effect of different drugs on the growth of SCC25 cells was screened by MTT assay. MTT, Hoechst33258 staining and FCM were used to observe the changes of morphology, cell cycle and apoptosis of SCC25 cells after different treatments. The quantitative analysis of chloroquine induced by Western blot The effect of chemotherapy drugs on the expression of Bax, Bcl-2 and NFkB apoptosis- related proteins in SCC25 cells. Results: The proliferation inhibition rate of bleomycin and nedaplatin SCC25 cells induced by chloroquine was significantly higher than that of bleomycin and nedaplatin alone (p<0.05); Hoechst33358 fluorescence staining and flow cytometry showed In the bleomycin group, the apoptotic rate of the chloroquine plus bleomycin group was significantly increased, and the apoptosis rate of the chloroquine + nedaplatin group was significantly higher than that of the nedaplatin group (p<0.05). The proportion of G0/G1 phase in the chloroquine + bleomycin group was higher than that in the bleomycin group (p<0.05), and the ratio of cells in the S phase to the G2/M phase was decreased; the same chloroquine + nedaplatin group G0/G1 The proportion of cells in the period was higher than that in the nedaplatin group (p<0.05), and the proportion of cells in the S phase and G2/M phase decreased. WB results showed that the expression levels of Bax and NFkB in chloroquine + bleomycin group were significantly higher than those in bleomycin group alone, and the expression level of Bcl-2 was lower than that in bleomycin group alone. Bax and NFkB in chloroquine + nedaplatin group The expression level was significantly higher than that of the nedaplatin group alone. The expression level of Bcl-2 was lower than that of the nedaplatin group alone, and the difference was significant (p<0.05). Conclusion: Chloroquine induced bleomycin and nedaplatin can significantly inhibit the proliferation of tongue squamous cell carcinoma SCC25 cells, and its proapoptotic effect may be related to the activation of mitochondrial apoptosis-related proteins and nuclear transcription factors.
References
Yu Lin, Gou baodi. research progress on anti-tumor activity and pulmonary fibrosis toxicity induced by bleomycin [J]. Baotou medical college journal, 2018, 34(11): 126-129.
Li Liyan. Study on the inhibitory effect of nedaplatin combined with ABT-737 on solid tumor cells and its mechanism [D]. Zhejiang University of Traditional Chinese Medicine, 2017.
Guan Yinghui; Experimental Study and Mechanism Discussion of Chloroquine's Anti-Hepatocellular Carcinoma Effect in Vitro; [D] Jilin University; 2010.
Ren Zhenhu, Wu Hanjiang. Research status of extracapsular invasion of cervical lymph nodes [J]. Journal of Practical Stomatology, 2012, 28(4): 837-840.
Chan HK, Ismail S. Side effects of chemotherapy among cancer patients in a Malaysian General Hospital:experiences, perceptions and informational needs from clinical pharmacists.[J]. Asian Pacific Journal of Cancer Prevention Apjcp, 2014, 15(13): 5305-9.
Hussein AA, Helder M N, de Visscher JG, et al. Global incidence of oral and oropharynx cancer in patientsyounger than 45 years versus older patients: A systematic review.[J]. European Journal of Cancer, 2017, 82: 115-127.
Yang Y H, Liu S H, Ho P S, et al. Conditional survival rates of buccal and tongue cancer patients: How far does the benefit go? [J]. Oral Oncology, 2009, 45(2): 177-183.
Osaka R, Yamamoto N, Nomura T, et al. Evaluation of infiltrative growth pattern in squamous cell carcinoma of the tongue: Comparison with Yamamoto-Kohama classification [J]. Journal of Oral & Maxillofacial Surgery Medicine & Pathology, 2015, 27(2): 250-254.
Yamamoto N, Osaka R, Watabe Y, et al. Clinical study of mode of invasion in tongue squamous cell carcinoma. Journal of Oral & Maxillofacial Surgery Medicine & Pathology, 2014, 26(3): 287-291.
Thomsen, A., Kolesar, J M. Chemoprevention of breast cancer. Am. J. Health Syst.Pharm. 2008, 65, 2221-2228.
Solomon VR, Lee H. Chloroquine and its analogs: a new promise of an old drug for effective and safe cancer therapies[J]. Euro J Phar- macol, 2009, 625(1): 220-233.
Solomon VR, Lee H. Chloroquine and its analogs: a new promise of an old drug for effective and safe cancer therapies[J]. Euro J Phar- macol, 2009, 625(1): 220-233.
Rosales-HernandezMC, Bermudez-LugoJ, GarciaJ, et al.Molecular modeling applied to anti-cancer drug development[J]. Anti-Cancer Agents Med Chem, 2009, 9(2): 230-231.
Faivre S, Djelloul S, Raymond E. New Paradigms in Anticancer Therapy: Targeting Multiple Signaling Pathways With Kinase Inhibitors[J]. Seminars in Oncology, 2006, 33(4): 407-420.
Hennig R, Ding X Z, Tong W G, et al. Effect of LY293111 in combination with gemcitabine in colonic cancer[J]. Cancer Letters, 2004, 210(1): 0-46.
Hosoya Y, Kitoh Y, Kobayashi E, et al. Combination effects of tamoxifen plus 5-fluorouracil on gastric cancer cell lines in vitro.[J]. Cancer Letters, 1999, 140(1-2): 139-143.
Balasubramanian K, Schroit A J. Aminophospholipid Asymmetry: A Matter of Life and Death[J]. Annual Review of Physiology, 2003, 65(1): 701-734.
Zhan Qimin, Chen Jie. Cell Cycle and Tumor Transformation Medicine [J]. Chinese Cancer Clinic, 2014 (01): 1-7.
cycle and tumor transformation medicine[J]. Chinese Journal of Clinical Oncology, 2014(01): 1-7. (in Chinese)
Sá, Ivone Manzali de. Chloroquine resistance and the search for antimalarial drugs from the 1960s to 1980s[J]. Hist. cienc. saude-Manguinhos, 2011, 18.
Cufí, Sílvia, Vazquez-Martin A, Oliveras-Ferraros C, et al. The anti-malarial chloroquine overcomes Primary resistance and restores sensitivity to Trastuzumab in HER2-positive breast cancer[J]. Scientific Reports, 2013, 3.
The anti-malarial chloroquine suppresses proliferation and overcomes cisplatin resistance of endometrial cancer cells via autophagy inhibition[J]. Gynecologic Oncology, 2015, 137(3): 538-545.
Copyright (c) 2019 Ruoyu Wang and Lan Yang
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
Authors contributing to this journal agree to publish their articles under the Creative Commons Attribution-Noncommercial 4.0 International License, allowing third parties to share their work (copy, distribute, transmit) and to adapt it, under the condition that the authors are given credit, that the work is not used for commercial purposes, and that in the event of reuse or distribution, the terms of this license are made clear. With this license, the authors hold the copyright without restrictions and are allowed to retain publishing rights without restrictions as long as this journal is the original publisher of the articles.
